… , and during this specific period exogenous surfactant treatment may be considered (11). …
Therefore, we decided to use budesonide combined with surfactant treatment to (i) minimize …

… Pediatric ALI/ARDS remains one of the leading causes of … Thus, surfactant therapy for
Pediatric ARDS, while it has still … key to future therapy is impeding the onset of fibrosis. Thus, …

… surfactants is to diminish surface tension in the alveoli at the air–liquid interface and inhibit
its collapse at … current results for SP-D in ALI/ARDS from preclinical and clinical studies. Our …

… Injury to alveolar type II cells contributes to surfactant … pathways associated with ALI/ARDS
at a molecular level and … or through aerosolization are other potential avenues for future study. …

… a description of completed and future clinical trials in humans with … a major pathogenic
role in ALI/ARDS. Despite promising … of aspirin administration on ARDS development in at-risk …

… Although ALI/ARDS modifying pharmacological agents have … confirming pharmacological
agent efficacy in future studies. … With the glucocorticoid effects on surfactant and ability to …

… Several studies have examined surfactant protein levels in … aspirate surfactant protein A
(SP-A) and surfactant protein B (… fluid from children with ARDS, while surfactant protein D (SP-D) …

… Owing to the distinctive characteristics of ALI/ARDS, … concentration at target sites while
decreasing drug concentration at non-… the future design of nano-formulations for siRNA inhalation …

… may provide great promises in treating ARDS in the future. … trial demonstrated that exogenous
surfactant therapy was only … neutrophil overactivation during ALI/ARDS releases cytotoxic …